Commercial Services and Supplies
Company Overview of Cancer Research UK
Cancer Research UK is a charitable institution that supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The charity also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. The institute also operates an online portal CancerHelp UK that provides patient information. Cancer Research UK was incorporated in 2001 and is based in London, United Kingdom.
407 St. John Street
London, EC1V 4AD
Founded in 2001
Key Executives for Cancer Research UK
Chief Executive Officer and Chairman of the Executive Board
Compensation as of Fiscal Year 2015.
Cancer Research UK Key Developments
Cancer Research UK Joins OHSU in Collaboration to Improve Early Detection of Cancer
Dec 15 15
Cancer Research UK and the Knight Cancer Institute at Oregon Health & Science University have formed an international collaboration to accelerate research in the early detection of cancer. The goal of this unique transatlantic agreement is to fill the urgent need for better methods to find lethal cancers as they are forming so that they can be treated more effectively. A patient's chance of survival increases significantly if the disease is diagnosed and treated at an early stage. The collaboration also seeks to accelerate progress by identifying and tackling the barriers for scientists, including: a lack of research models for the earliest stages of the disease; a shortage of tissue samples available for research, especially samples from higher risk patients; Limited funding for this type of research; and the need for a better understanding of the biology of early cancer and appropriate technologies to detect its features.
BioInvent International Reaches Agreement with Cancer Research UK, and Leukaemia & Lymphoma Research to Take its Investigational Drug
Jan 20 15
BioInvent International reached an agreement with Cancer Research UK, and Leukaemia & Lymphoma Research to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL). The first in man study will be funded and conducted by Cancer Research UK, CRT and LLR. BioInvent has been granted the option to take up an exclusive license to the study data, subject to payment of milestones and royalties to Cancer Research Technology. BI-1206 is a fully-human anti-CD32b antagonistic antibody that in addition to directly killing tumour cells is thought to work by maintaining CD20 antibodies on the cell membrane of cancer cells, preventing them from becoming resistant to the current treatment, rituximab. The antibody has shown promise both in combination with CD20 antibodies and as a single agent in chronic lymphocytic lymphoma (CLL) and other types of NHL, in an extensive package of preclinical studies carried out by Leukaemia & Lymphoma Research-funded scientists at the University of Southampton. The potential development opportunity for BI-1206 may extend well beyond NHL. The open label Phase I/ll study will enroll between 50 and 60 patients who will receive either BI-1206 alone or BI-1206 in combination with rituximab. The study will primarily enroll CLL patients but smaller cohorts of patients with other types of NHL, such as mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma, may also be recruited. The study is expected to commence in the second half of 2015. It is the first drug to be entered into a new partnership through which Cancer Research UK and Leukaemia & Lymphoma Research will be jointly funding early phase clinical trials for patients with blood cancers. Cancer Research UK's CDD will manage and sponsor the study through the Experimental Cancer Medicine Centre (ECMC) network, with Leukaemia & Lymphoma Research providing the majority of the funding.
MedImmune Enter into Collaboration with Cancer Research UK and Cancer Research Technology to Jointly Establish Biologic Cancer Medicine Lab
Sep 29 14
MedImmune has entered into a collaboration with Cancer Research UK and its Cancer Research Technology (CRT). The collaboration is intended to jointly establish a laboratory in Cambridge, UK, to focus on the discovery and development of novel biologic cancer treatments over an initial five-year period. Scientists from both organizations will work side-by-side on multiple oncology projects at the new CRUK-MEDI Alliance Laboratory. Cancer Research UK, will provide set-up and operational funding for the laboratory and will contribute a portfolio of novel drug targets together with a team of scientists. MedImmune will oversee the laboratoryactivities and provide access to its human antibody phage display libraries and established antibody-engineering technologies. The joint team will share knowledge and expertise to discover and develop antibodies to treat cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries